Patents by Inventor Kenneth K. Iwata
Kenneth K. Iwata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11833149Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: GrantFiled: January 10, 2022Date of Patent: December 5, 2023Assignee: OSI Pharmaceuticals, LLCInventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
-
Publication number: 20220133725Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: ApplicationFiled: January 10, 2022Publication date: May 5, 2022Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
-
Patent number: 11253520Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: GrantFiled: January 24, 2020Date of Patent: February 22, 2022Assignee: OSI Pharmaceuticals, LLCInventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
-
Publication number: 20200230142Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: ApplicationFiled: January 24, 2020Publication date: July 23, 2020Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
-
Patent number: 10583142Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: GrantFiled: March 25, 2016Date of Patent: March 10, 2020Assignee: OSI Pharmaceuticals, LLCInventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
-
Publication number: 20170273982Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: ApplicationFiled: March 25, 2016Publication date: September 28, 2017Inventors: Stanley C. GILL, Kenneth K. IWATA, Gregory J. RIELY, Jun WU, Helena YU
-
Patent number: 6586394Abstract: This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.Type: GrantFiled: January 27, 1994Date of Patent: July 1, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 6559123Abstract: This invention is directed to a method of treating a burn or healing a wound in a mammal by administering a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide.Type: GrantFiled: August 22, 1994Date of Patent: May 6, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 6425769Abstract: The invention provides a recombinant nucleic acid vector comprising a nucleic acid encoding a polypeptide of 112 amino acids having the amino acid sequence shown in FIG. 29 beginning with alanine at position 1 and ending with serine at position 112. The sequence of FIG. 29 represents a member of the TGF-&bgr; family of tumor growth factors. The invention also provides a method for producing a protein which comprises culturing the host cell under conditions suitable to express the protein in the host cell and recovering the protein so produced.Type: GrantFiled: June 1, 1995Date of Patent: July 30, 2002Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Peter ten Dijke
-
Patent number: 5871724Abstract: The present invention provides a method for inhibiting cytotoxic poisoning of normal cells in a subject which comprises administering to the subject an amount of a Transforming Growth Factor Beta effective to slow the growth of normal cells and thereby inhibit the cytotoxic poisoning of the normal cells in the subject. Typically, administration is topical and initiated prior to anti-neoplastic therapy such as radiation treatment or chemotherapy. The invention is particularly suited for pediatric patients.Type: GrantFiled: June 7, 1995Date of Patent: February 16, 1999Assignee: O.S.I. Pharmaceuticals Inc.Inventors: Kenneth K. Iwata, J. Gordon Foulkes, Peter Ten Dijke, John D. Haley
-
Patent number: 5824297Abstract: The present invention provides a method for inhibiting cytotoxic poisoning of normal cells in a subject which comprises administering to the subject an amount of a Transforming Growth Factor Beta effective to slow the growth of normal cells and thereby inhibit the cytotoxic poisoning of the normal cells in the subject. Typically, administration is topical and initiated prior to anti-neoplastic therapy such as radiation treatment or chemotherapy. The invention is particularly suited for pediatric patients.Type: GrantFiled: September 1, 1993Date of Patent: October 20, 1998Assignee: Oncogene Science, Inc.Inventors: Kenneth K. Iwata, J. Gordon Foulkes, Peter Ten Dijke, John D. Haley
-
Patent number: 5262319Abstract: The present invention provides (1) an antibody which (a) specifically binds to human TGF-.beta.3 and (b) exhibits substantially no cross reactivity with TGF-.beta.1 or TGF-.beta.2 and (2) antibodies directed against the pro region of the TGF-.beta. precursor. Further, this invention provides a pharmaceutical composition comprising the pro region of the TGF-.beta. precursor. Also, this invention provides methods for diagnosing, detecting and treating subjects suffering from disorders associated with TGF-.beta.3.Type: GrantFiled: June 25, 1990Date of Patent: November 16, 1993Assignee: Oncogene Science, Inc.Inventors: Kenneth K. Iwata, J. Gordon Foulkes, Peter T. Dijke, John D. Haley
-
Patent number: 4708948Abstract: A substantially purified substance having the property of inhibiting tumor cell growth without inhibiting the growth of normal human cells and without having antiviral effect, further having the properties of: (a) ranging from about 3,500 to 45,000 daltons in molecular weight; (b) being heat stable at about 56.degree. C. when exposed for about 30 minutes; (c) possessing isoelectric point ranging from pI 4-8; and (d) eluting on high pressure liquid chromatography at about 10-35% of 2-propanol or about 25-50% of acetonitrile gradient, has been disclosed. The substance has utility as an antitumor or antineoplastic agent. The substance may also be useful as an index or tumorgenic activity in an organism. The mitogenic and growth stimulatory activity possessed by the substance of the present invention may be useful in wound healing and treating burn-victims.Type: GrantFiled: April 20, 1984Date of Patent: November 24, 1987Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth K. Iwata, Charlotte M. Fryling, George J. Todaro